We are live on ! Find out more
LEXXW

Lexaria Bioscience Warrant
LEXXW

Delisted

LEXXW was delisted on the 13th of January, 2026.

Back to rankings

4 hedge funds and large institutions have $303K invested in Lexaria Bioscience Warrant in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

69% less capital invested

Capital invested by funds: $991K → $303K (-$688K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$5.26K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$32.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$194K – – –
SM
2
Sabby Management
Florida
$87.9K -$32.9K -65,547 -23%
CH
3
CVI Holdings
Delaware
$16.8K – – –
Citadel Advisors
4
Citadel Advisors
Florida
$4.2K +$5.26K +10,496 New

LEXXW Hedge Fund Activity: Q4 2022 in Review

4 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q4 2022, worth a combined $303K — down 69% from $991K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new LEXXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $5.26K. The largest seller was Sabby Management, cutting an estimated $32.9K.

  • 4 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $303K of Lexaria Bioscience Warrant stock for Q4 2022, down 69% quarter-over-quarter.
  • 1 fund opened new Lexaria Bioscience Warrant positions in Q4 2022 and 0 closed out, a net change of +1 holder.
  • The largest Lexaria Bioscience Warrant buyer in Q4 2022 was Citadel Advisors, an estimated $5.26K added.
  • The largest Lexaria Bioscience Warrant seller in Q4 2022 was Sabby Management, an estimated $32.9K sold.

Based on aggregated 13F filings for Q4 2022.